A randomised, double-blind, placebo-controlled, multicentre prospective dose-finding Phase II/III study with atacicept given subcutaneously to subjects having recently experienced a flare of systemic lupus erythematosus (SLE)

The primary objective of this trial is to evaluate the efficacy of atacicept compared to placebo in preventing new flares in subjects with SLE.

Kusajili – Centralise les essais cliniques mondiaux